As a member of the HCCC, we are commenting on this question, however we must acknowledge the barrier in doing so without understanding the entirety of the approach to connect the creation of the pilot list to a functional national formulary. [...] Should the deliberative process include weighting of the evidence or a score for each criterion? No response provided If yes, how should weight be distributed among the proposed criteria? As a member of the HCCC, we recognize the importance of a governance model to a successful national formulary and support a governance model that is objective and takes into account authentic and regular patient. [...] We endorse the response to the PCF Consultation submitted by Innovative Medicines Canada and BIOTECanada, and we would like to emphasize some key aspects: 1) Context and Scoping of PCF Framework The scope of the current consultation exercise is limited to the development of the PCF list, but specifically excludes discussion of its implementation. [...] Apotex supports the recommendations in the Final Report of the Advisory Council on the Implementation of National Pharmacare for mandatory generic substitution policies to encourage patients and prescribers to choose the most cost-effective therapies, and increase patient and prescriber awareness about the equivalency of generic and brand-name prescription medicines. [...] With the steep increase in the use and cost of new medications and related products over the past decade and with an aging population with many chronic illnesses, decisions concerning the addition of a drug to the formulary must take into account the survival of the coverage plan if a drug (and similar drugs) is to be added.
- Pages
- 430
- Published in
- Canada
